Rigel Pharmaceuticals, Inc.  

(Public, NASDAQ:RIGL)   Watch this stock  
Find more results for RIGL
+0.01 (0.39%)
After Hours: 2.60 0.00 (0.00%)
Oct 24, 5:09PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.51 - 2.62
52 week 1.88 - 4.38
Open 2.58
Vol / Avg. 2.29M/1.76M
Mkt cap 245.93M
P/E     -
Div/yield     -
EPS -0.56
Shares 94.59M
Beta 1.18
Inst. own 92%
Nov 1, 2016
Q3 2016 Rigel Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 30, 2016
Rigel Pharmaceuticals Inc Conference Call to Discuss Its First of Two FIT Phase 3 Results of Fostamatinib - Webcast
Aug 2, 2016
Q2 2016 Rigel Pharmaceuticals Inc Earnings Call
Aug 2, 2016
Q2 2016 Rigel Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -157.47% -178.11%
Operating margin -158.81% -179.07%
EBITD margin - -174.09%
Return on average assets -52.29% -36.00%
Return on average equity -72.78% -46.86%
Employees 126 -
CDP Score - -


1180 Veterans Blvd
United States - Map
+1-650-6241100 (Phone)
+1-650-6241101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura (ITP); a Phase II clinical trial for autoimmune hemolytic anemia (AIHA), and a Phase II clinical trial for IgA nephropathy (IgAN). It has approximately two oncology product candidates in Phase I development. The Company is also engaged in conducting research in the disease areas of inflammation/immunology, and muscle wasting/muscle endurance, among others. Its product pipeline includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor. The R348 product candidate is in Phase II clinical trials for the treatment of dry eye in patients with ocular graft-versus-host disease (GvHD).

Officers and directors

Raul R Rodriguez President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Ryan D. Maynard Chief Financial Officer and Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Eldon C. Mayer III Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Anne-Marie Duliege M.D. Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Keith A. Katkin Director
Age: 43
Bio & Compensation  - Reuters
Bradford S. Goodwin Independent Director
Age: 60
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 56
Bio & Compensation  - Reuters
Walter H. Moos Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Peter S. Ringrose Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters